Oral mucosal immunotherapy for allergic rhinitis: A pilot study
Abstract
Background: The sublingual mucosa has been used for many years to apply allergenic extracts for the purpose of specific immunotherapy (IT). Although sublingual IT (SLIT) is both safe and efficacious, the density of antigen-presenting cells is higher in other regions of the oral cavity and vestibule, which make them a potentially desirable target for IT.
Objective: To present the concept of oral mucosal IT (OMIT) and to provide pilot data for this extended application of SLIT.
Methods: An open-label, 12-month, prospective study was undertaken as a preliminary step before a full-scale clinical investigation. Twenty-four individuals with allergic rhinitis received IT by applying allergenic extracts daily to either the oral vestibule plus oral cavity mucosa by using a glycerin-based toothpaste or to the sublingual mucosa by using 50% glycerin liquid drops. Adverse events, adherence rates, total combined scores, rhinoconjunctivitis quality-of-life questionnaire scores, changes in skin reactivity, and changes in serum antibody levels were measured for each participant.
-
Most popular related searches
Customer comments
No comments were found for Oral mucosal immunotherapy for allergic rhinitis: A pilot study. Be the first to comment!